{"eventGroups":[{"deathsNumAffected":3,"deathsNumAtRisk":80,"description":"Patients receive trivalent influenza vaccine IM at weeks 1, 9, and 17, and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity.\n\nPneumococcal 13-valent Conjugate Vaccine: Given IM\n\nTrivalent Influenza Vaccine: Given IM","id":"EG000","otherNumAffected":0,"otherNumAtRisk":80,"seriousNumAffected":0,"seriousNumAtRisk":80,"title":"Arm I (Trivalent Influenza Vaccine, Prevnar)"},{"deathsNumAffected":1,"deathsNumAtRisk":85,"description":"Patients receive trivalent influenza vaccine IM at week 1 and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity.\n\nPneumococcal 13-valent Conjugate Vaccine: Given IM\n\nTrivalent Influenza Vaccine: Given IM","id":"EG001","otherNumAffected":0,"otherNumAtRisk":85,"seriousNumAffected":0,"seriousNumAtRisk":85,"title":"Arm II (Trivalent Influenza Vaccine, Prevnar)"}],"frequencyThreshold":"2","timeFrame":"1 year"}